Investors & Media

Transformative science, targeted medicines

Blueprint Medicines, a Sanofi company, is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine AYVAKIT/AYVAKYT® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.

Biography

<< Back

Tanya Green

Senior Vice President, Chief of Staff

Tanya Green brings more than 20 years of biopharmaceutical industry leadership experience, with a strong track record of clinical development and commercialization. Throughout her career, she has successfully secured numerous regulatory approvals for rare disease and oncology therapies, including AYVAKIT®, GAVRETO®, CERDELGA® and KANUMA®. Since joining Blueprint Medicines in January 2017 as Director of Regulatory Affairs, Tanya has played a pivotal role in the company’s success. She served as the regulatory lead on the avapritinib program, obtaining the company’s first regulatory approval. In March 2020, Tanya was appointed Head of Global Regulatory Sciences and subsequently Senior Vice President, where she was integral in building a diverse, high-growth global organization while fostering a strong company culture. Previously, Tanya held regulatory affairs roles at Alexion and Genzyme. She holds a B.S. in Biology from Suffolk University and an M.S. in Regulatory Affairs and Health Policy from the Massachusetts College of Pharmacy and Health Sciences.